86123-11-7 Usage
Description
Fmoc-D-tryptophan, also known as Nα-Fmoc-D-tryptophan, is an N-Fmoc-protected form of D-tryptophan, an unnatural isomer of the essential amino acid L-tryptophan. It is a beige powder and has been synthesized as part of potent Oxytocin antagonists for the treatment of preterm labor.
Uses
Used in Pharmaceutical Industry:
Fmoc-D-tryptophan is used as a building block for the synthesis of peptides and peptidomimetics, particularly in the development of Oxytocin antagonists for the treatment of preterm labor. Its N-Fmoc protection allows for selective deprotection and coupling reactions in peptide synthesis, facilitating the production of complex peptide structures.
Used in Research and Development:
Fmoc-D-tryptophan is utilized as a research compound for studying the properties and functions of D-tryptophan and its analogs. It aids in understanding the differences between Dand L-amino acids and their roles in biological systems, as well as their potential applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 86123-11-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,1,2 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 86123-11:
(7*8)+(6*6)+(5*1)+(4*2)+(3*3)+(2*1)+(1*1)=117
117 % 10 = 7
So 86123-11-7 is a valid CAS Registry Number.
InChI:InChI=1/C26H22N2O4/c29-25(30)24(13-16-14-27-23-12-6-5-7-17(16)23)28-26(31)32-15-22-20-10-3-1-8-18(20)19-9-2-4-11-21(19)22/h1-12,14,22,24,27H,13,15H2,(H,28,31)(H,29,30)/p-1/t24-/m1/s1
86123-11-7Relevant articles and documents
Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety
Zhu, Lunan,Zhu, Junchen,Sun, Xiaotong,Wu, Yaling,Wang, Huiying,Cheng, Lingping,Shen, Jiawei,Ke, Yanxiong
, p. 1080 - 1090 (2020/05/25)
Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.
